These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
243 related items for PubMed ID: 20473174
1. Bisphosphonate adverse effects, lessons from large databases. Abrahamsen B. Curr Opin Rheumatol; 2010 Jul; 22(4):404-9. PubMed ID: 20473174 [Abstract] [Full Text] [Related]
2. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538 [Abstract] [Full Text] [Related]
4. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. Mavrokokki T, Cheng A, Stein B, Goss A. J Oral Maxillofac Surg; 2007 Mar; 65(3):415-23. PubMed ID: 17307586 [Abstract] [Full Text] [Related]
7. Osteonecrosis of the jaw: balancing the benefits and risks of oral bisphosphonate treatment for osteoporosis. Jeffcoat M, Watts NB. Gen Dent; 2008 Mar; 56(1):96-102; quiz 103-4, 111-2. PubMed ID: 18254568 [Abstract] [Full Text] [Related]
8. Benefits and risks of bisphosphonate therapy for osteoporosis. Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT. J Clin Endocrinol Metab; 2012 Jul; 97(7):2272-82. PubMed ID: 22523337 [Abstract] [Full Text] [Related]
9. Long-term use of bisphosphonates in osteoporosis. Watts NB, Diab DL. J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017 [Abstract] [Full Text] [Related]
10. Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S. Skrepnek GH, Seal B, Tangirala M, Jeffcoat MK, Watts NB, Hay JW. Gen Dent; 2010 Apr; 58(6):484-92; quiz 493-4. PubMed ID: 21062718 [Abstract] [Full Text] [Related]
11. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. Grant BT, Amenedo C, Freeman K, Kraut RA. J Oral Maxillofac Surg; 2008 Feb; 66(2):223-30. PubMed ID: 18201600 [Abstract] [Full Text] [Related]
18. Bisphosphonate-related osteonecrosis of the jaw in cancer patients: Implications for nurses. Morris M, Cruickshank S. Eur J Oncol Nurs; 2010 Jul; 14(3):205-10. PubMed ID: 20129822 [Abstract] [Full Text] [Related]
19. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM. Am J Med; 2013 Jan; 126(1):13-20. PubMed ID: 23177553 [Abstract] [Full Text] [Related]
20. Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates? Diel IJ, Fogelman I, Al-Nawas B, Hoffmeister B, Migliorati C, Gligorov J, Väänänen K, Pylkkänen L, Pecherstorfer M, Aapro MS. Crit Rev Oncol Hematol; 2007 Dec; 64(3):198-207. PubMed ID: 17855108 [Abstract] [Full Text] [Related] Page: [Next] [New Search]